

QVQ Targets

Jun-19



QVQ Targets											
Cancer			Infectious diseases			Age related diseases					
						Tissue Repair		Neuromuscular		Cardiovascular	
Target	CD #	Phase	Target	CD #	Phase	Target	CD #	Phase	Target	CD #	Phase
Her 2	CD340	5 *	Clostridium difficile toxin B		5	BMP4		5	Vimentin		5
BMP2/4		5	HIV neutr. CD4bs (J3)		5	BMP7		5	PABPN1		5
CA IX		5	HIV various bi-heads		5	Hydroxyapatite (HA)		5	CXCR4	CD184	4
CEA		5	Rotavirus		5	CXCR4	CD184	4	DUX4		4
EGFR		5	Vimentin		5	DKK		4	Integrin β1	CD29	4
Vimentin		5	Candida albicans ECE1		4	DNABII		4	NCAM	CD56	4
B7H3	CD276	4	Clostridium difficile toxin A		4	Integrin β1	CD29	4	Tf Receptor	CD71	4
cMet		4	CXCR4	CD184	4	VEGF		4	Amyloid β		3
CXCR4	CD184	4	DCSign		4	B7-1	CD80	3	BACE		3
EpCAM	CD326	4	DNABII		4	BMP6		3	FcyRIII	CD16	3
Integrin β1	CD29	4	HIV neutr. Bridging sheet		4	Collagen		3	IL1-R	CD121	3
NCAM	CD56	4	HIV neutr. gp41		4	Fibronectin [FN]		3			
PD-L1	CD274	4	HIV neutr. gp41/gp140		4	IL1-R	CD121	3			
PD-L2	CD273	4	HIV neutr. V3 loop		4	MST1R	CD136	3			
PSA		4	P24 (HIV)		4	RM3/1 antigen	CD163	3			
VLA-3 integrin	CD49c	4	Candida alb. Germtubes		3	Vitronectin		3			
Tf Receptor	CD71	4	Candida alb. Hyphae		3						
uPAR		4	Norovirus		3						
VEGF		4	Pseudomonas Flaggelum		3						
CAVII		3									
Hyaluronic acid receptor	CD44	3									
PKC ε		3									
PKC θ		3									
T cell receptor	CD3	3									
Targets under investigation											
CTLA-4	CD152	2	Flippase		2	Sclerostin SOST		2	CD14	CD14	2
BMP-R1		2	NEF (HIV)		2	Aggrecan		1	CRYM1		2
Eps15		2	OMP E.Coli		2	Folate Receptor		1	Dysferlin		2
Her3		2	OMP T		2	IL1β		1	Emerin		2
HIF1α		2	S. aureus		2	Matrilin		1	FRG1		2
Hyaluronic acid receptor v6	CD44v6	2	S. epidermidis		2	MMP13		1	HMGB1		2
p53		1	CCR5	CD195	1				Huntingtin		2
OX40L	CD252	1	E. faecium		1				MPO		2
4-1BB Ligand	CD137L	1							GABARAPL1		1
CCR5	CD195	1							Myostatin		2
SLC amino acid transporters		1							PITX1		2
									Tropomyosin		2
									Actin		1
									IL1β		1
									p53		1

Phases explained

5*	VHH characterized <i>in vivo</i> . Produced under GMP conditions.
5	VHH characterized <i>in vivo</i> . Purified VHH (C-Direct) available from yeast production. Ready for GMP production.
4	VHH has been characterized <i>in vitro</i> . Purified VHH available from E.coli production.
3	Lead molecules with high affinity have been identified. Ready for characterization <i>in vitro</i> .
2	Selections for monoclonal VHH were performed. Ready for further characterization.
1	Immunizations of llamas were performed. Ready for monoclonal VHH selection.